JDRF is striving to accomplish a feat that has never been achieved before: permanently turning off an autoimmune response in humans. The JDRF Immunotherapy Program aims to turn off the deadly attack against beta cells that causes type 1 diabetes (T1D). We power groundbreaking research and development of new therapies that will stop the autoimmune attack at its earliest stages.
Our immune systems protect us against threats from within and without. In people with T1D, the immune system mistakes the body’s own cells for dangerous invaders and targets the pancreas’ insulin-producing beta cells. As a result of beta cell death, people with T1D depend on external insulin to survive.
so progression to T1D never happens
that can control and inhibit killer cells
for continued immune control against beta cells
Our research into immunotherapy technologies is just one potential pathway to finding a cure. Explore JDRF’s ambitious research portfolio.
A new study shows that a specific combination of immunotherapy drugs may help insulin-producing islet cells survive and function better in people with T1D.
JDRF partners with AnTolRx, a developer of nanoparticle-based therapies to treat autoimmune diseases, to use the company’s technology for T1D.
TetraGenetics used its proprietary technology to discover a pool of novel monoclonal antibodies that inhibit immune activity, which could play a role in treating T1D.
Researchers, both of whom were JDRF grantees, report that a clinical trial of the drug methyldopa, used for over 50 years to treat high blood pressure, might delay the progression of new-onset T1D.
To date, more than $145 million has been invested by JDRF on immunotherapy research. We are striving to accomplish a feat that has never been achieved before: permanently turning off an autoimmune response in humans.